(AOF) – The Neovacs Board of Directors has decided to carry out a capital reduction, motivated by losses by way of reduction of the par value of the share. The company specializing in therapeutic vaccines targeting the treatment of autoimmune diseases specifies that the par value of the share is therefore reduced from 0.01 euro to 0.0005 euro. The share capital divided into 162,721,650 shares has been reduced from 1,627,216.50 euros to 81,360.8250. Neovacs shares lost 5.56% today at 0.051 euro. It has lost 57.50% of its value for one month and 91.37% over three months.
AOF – LEARN MORE
Find out more about the “pharmacy” sector
Loss of speed in European research
European research is losing ground to American and Chinese research. In twenty years, Europe’s share has fallen from 41% to 31% in global R&D. China’s share jumped from 1% to 8%. As for the United States, which supplanted Europe, in 2001 it devoted only 2 billion euros per year more than Europe to R&D, whereas now this gap has reached 25 billion! Some experts accuse the European authorities of not having deployed effective policies. The financing of pharmaceutical research should therefore have been better targeted via the “Horizon 2020” programme. France only comes in eighteenth position in European funding despite the quality of its research. Conversely, the United States concentrates funding on Boston and a few centers of excellence.